It states twice withing the first couple pages of the S-1 that they will reverse split. That seems like a pretty strong indication. And it's outside of the risk factors section, so it's not something they are saying is a possibility, they are saying they will do it in order to uplist to Nasdaq.
Now I'm sure if they release good news on mice trials or get FDA emergency authorization for covid treatment they will not need to reverse split. But per the S-1 they as of yet have not received FDA approval of any kind. That could change, and I am very hopeful it will, but as things stand as of now and with the history of this stock and reverse splits, this is not news to just be brushed off without some consideration.
Luckily, we have time to see what happens with the share price. The coming weeks will be critical. Hopefully they will release mice trial results and that will push the share price up where it needs to be for Nasdaq. Anyone that believes this company will come through with flying colors should not be concerned about people speculating on ihub.